Moleculin Biotech, Inc. is preclinical and clinical-stage pharmaceutical company focused on the development of game-changing anti-cancer drug candidates, many of which are based on discoveries made at M.D. Anderson Cancer Center. Each of our projects represents a breakthrough discovery and a highly disruptive technology.

Income Statement

v3.8.0.1
Statements of Operations - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Sep. 30, 2017
Sep. 30, 2016
Income Statement [Abstract]        
Revenues $ 0 $ 0 $ 0 $ 0
Operating expenses:        
Research and development 1,061 497 2,260 616
General and administrative 1,338 924 2,987 1,848
Depreciation 5 1 13 2
Total operating expenses 2,404 1,422 5,260 2,466
Loss from operations (2,404) (1,422) (5,260) (2,466)
Other income (expense):        
Loss from change in fair value of warrant liability (470) 0 (2,753) 0
Gain from settlement of liability 0 0 149 0
Gain from expiration of warrants 0 0 1,238 0
Other income 9 0 8 0
Interest expense (1) (10) (2) (37)
Net loss $ (2,866) $ (1,432) $ (6,620) $ (2,503)
Net loss per common share – basic and diluted (in dollars per share) $ (0.14) $ (0.12) $ (0.37) $ (0.28)
Weighted average common shares outstanding – basic and diluted 20,534,720 11,579,239 17,683,441 9,066,804

Source